Sanofi

🇫🇷France

Country: 🇫🇷France

Ownership: Public

Employees: 87.9K

Market Cap: $141.3B

Website: http://www.sanofi.com

Introduction: Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Clinical Trials

Dermacyd Femina (Lactic Acid) - Photo Dermatological Evaluation of the Irritation and Sensitivity Potential.

Phase 3

Completed

Conditions: Hygiene

Interventions: Drug: Lactic acid (Dermacyd Femina)

First Posted Date: 2008-06-26

Last Posted Date: 2009-04-15

Lead Sponsor: Sanofi

Target Recruit Count: 26

Registration Number: NCT00705744

Locations: 🇧🇷
Sanofi-aventis, São Paulo, Brazil

Combination of Docetaxel + Estramustine + Hydrocortisone Versus Docetaxel + Prednisone in Patients With Advanced Prostate Cancer

Phase 3

Terminated

Conditions: Prostatic Neoplasms

Interventions: Drug: Docetaxel + Prednisone
Drug: Docetaxel + Estramustine + Hydrocortisone

First Posted Date: 2008-06-26

Last Posted Date: 2010-11-30

Lead Sponsor: Sanofi

Target Recruit Count: 54

Registration Number: NCT00705822

Locations: 🇪🇸
Sanofi-Aventis Administrative Office, Barcelona, Spain

A Study of XL765 (SAR245409) in Combination With Temozolomide With and Without Radiation in Adults With Malignant Gliomas

Phase 1

Completed

Conditions: Mixed Gliomas
Malignant Gliomas
Glioblastoma Multiforme

Interventions: Drug: XL765 (SAR245409)
Drug: Temozolomide

First Posted Date: 2008-06-24

Last Posted Date: 2013-04-10

Lead Sponsor: Sanofi

Target Recruit Count: 54

Registration Number: NCT00704080

Locations: 🇺🇸
Investigational Site Number, Cleveland, Ohio, United States

Assessment of Insulin Glargine in Type 2 Patients for Good Glycemic Control

Phase 4

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Insulin glargine

First Posted Date: 2008-06-19

Last Posted Date: 2010-11-04

Lead Sponsor: Sanofi

Target Recruit Count: 241

Registration Number: NCT00701831

Locations: 🇹🇷
Sanofi-Aventis Administrative Office, Istanbul, Turkey

A Study of AVE8062 in Advanced-stage Soft Tissue Sarcoma After Failure of Anthracycline and Ifosfamide Chemotherapies

Phase 3

Completed

Conditions: Sarcoma

Interventions: Drug: Placebo
Drug: OMBRABULIN (AVE8062)

First Posted Date: 2008-06-18

Last Posted Date: 2015-12-21

Lead Sponsor: Sanofi

Target Recruit Count: 355

Registration Number: NCT00699517

Locations: 🇺🇸
Investigational Site Number 840005, Maywood, Illinois, United States
🇺🇸
Investigational Site Number 840004, Santa Monica, California, United States
🇺🇸
Investigational Site Number 840007, Philadelphia, Pennsylvania, United States

and more 42 locations

Cohort Study in Uganda Comparing Artesunate + Amiodaquine (Coarsucam) Versus Artemether + Lumenfantrine (Coartem) in the Treatment of Repeated Uncomplicated Plasmodium Falciparum Malaria Attacks

Phase 4

Completed

Conditions: Malaria

Interventions: Drug: Coartem
Drug: Coarsucam

First Posted Date: 2008-06-18

Last Posted Date: 2010-06-29

Lead Sponsor: Sanofi

Target Recruit Count: 413

Registration Number: NCT00699920

Locations: 🇺🇬
Sanofi-aventis administrative office, Kampala, Uganda

European Trial of Dronedarone in Moderate to Severe Congestive Heart Failure

Phase 3

Terminated

Conditions: Congestive Heart Failure

Interventions: Drug: Dronedarone (SR33589)
Drug: Placebo

First Posted Date: 2008-06-13

Last Posted Date: 2010-02-15

Lead Sponsor: Sanofi

Target Recruit Count: 653

Registration Number: NCT00696631

Locations: 🇸🇪
Sanofi-aventis Administrative Office, Bromma, Sweden

Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Total Hip Replacement Surgery

Phase 3

Completed

Conditions: Venous Thromboembolism

Interventions: Drug: Semuloparin sodium
Drug: Enoxaparin sodium
Drug: Placebo

First Posted Date: 2008-06-13

Last Posted Date: 2013-01-23

Lead Sponsor: Sanofi

Target Recruit Count: 2326

Registration Number: NCT00697099

Locations: 🇦🇺
sanofi-aventis Australia & New Zealand administrative office, Macquarie Park, New South Wales, Australia
🇨🇳
Sanofi-Aventis Administraive Office, Taipei, Taiwan
🇺🇦
Sanofi-Aventis Administrative Office, Kiev, Ukraine

European Study of Dronedarone in Atrial Fibrillation

Phase 3

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: Placebo
Drug: Dronedarone (SR33589)

First Posted Date: 2008-06-13

Last Posted Date: 2009-07-30

Lead Sponsor: Sanofi

Target Recruit Count: 174

Registration Number: NCT00697086

Locations: 🇨🇭
Sanofi-aventis Administrative Office, Geneva, Switzerland

Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy

Phase 3

Completed

Conditions: Venous Thromboembolism
Cancer

Interventions: Drug: Placebo (for semuloparin)
Drug: Semuloparin sodium

First Posted Date: 2008-06-10

Last Posted Date: 2013-01-23

Lead Sponsor: Sanofi

Target Recruit Count: 3212

Registration Number: NCT00694382

Locations: 🇺🇸
Investigational Site Number 840064, Torrington, Connecticut, United States
🇺🇸
Investigational Site Number 840025, Washington, District of Columbia, United States
🇺🇸
Investigational Site Number 840029, West Covina, California, United States

and more 408 locations

Home Terms & Conditions Privacy Policy